Results of a randomized, placebo-controlled, phase 2 study of tarex-tumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC) Meeting Abstract
| Authors: | Daniel, D. B.; Rudin, C. M.; Hart, L.; Spigel, D. R.; Edelman, M. J.; Goldschmidt, J.; Bordoni, R.; Glisson, B.; Burns, T. F.; Dowlati, A.; Dy, G.; Beck, T. J.; Jotte, R.; Liu, S. V.; Kapoun, A.; Faoro, L.; Chiang, A. C. |
| Abstract Title: | Results of a randomized, placebo-controlled, phase 2 study of tarex-tumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC) |
| Meeting Title: | 42nd ESMO Congress (ESMO 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2017 Sep 8-12 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-09-01 |
| Start Page: | mdx386.004 |
| Language: | English |
| ACCESSION: | WOS:000411324003317 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx386.004 |
| Notes: | Meeting Abstract: 1530PD -- Appears on page 540 of the abstract book -- Source: Wos |
